Healthcare
CVRx, Inc.(CVRX)
Live Price
Offline$4.95
+2.48% today
1Y Change
-16.61%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $200.00M
- Revenue Growth
- +10.4%
- EPS Growth
- +23.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CVRx, Inc. (CVRX) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $4.95 and down 16.6% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +10.4%, EPS growth of +23.0%, a dividend yield of 0.0%. What stands out right now is revenue +10.4%, EPS +23.0%, free cash flow -0.6% with operating margin -90.5% and ROIC -56.0%. Valuation is more restrained than many high-expectation growth names at price/sales 3.5. Stock Foundry combines CVRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.4% vs +7.6% peer median
Operating Margin
Below sector median
-90.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.4% and EPS at +23.0%, with operating margin around -90.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +4.4% | +5.7% | -12.4% |
2026 Feb 12, 2026 | -9.5% | -13.0% | +7.4% | +32.3% |
2025 Nov 5, 2025 | +2.0% | +2.7% | -2.8% | -4.5% |
Benchmark Edge
CVRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CVRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CVRX Max Drawdown
-56.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CVRX and SPY.
Company Overview
CVRx, Inc.
NASDAQ
CVRx, Inc. is a pioneering medical device company that focuses on developing innovative therapies to address a variety of cardiovascular conditions. The company's primary product is the Barostim Neo, a neuromodulation device designed to improve heart function by stimulating the bodyโs baroreceptors, which are essential for regulating blood pressure. CVRx aims to enhance the quality of life for patients with chronic heart failure and other cardiovascular diseases by offering this alternative treatment to traditional drug therapies. With a growing presence in the medical technology industry, CVRx, Inc. collaborates with healthcare providers and institutions worldwide to expand its reach and impact. Founded with a commitment to advancing patient care, the company plays a significant role in the cardiovascular segment, contributing to ongoing improvements in non-invasive treatment options. Headquartered in Minneapolis, Minnesota, CVRx continues to focus on research and development to further refine its technology and expand its product applications in the field of heart health management.
- Leadership
- Mr. Kevin Hykes
- Employees
- 223
- Street Address
- 9201 West Broadway Avenue, Suite 650
- Mailing
- Minneapolis, MN, 55445
- Region
- Minneapolis, MN, United States
- Last Updated
- May 9, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.5
- Price/Book
- 5.0
Growth
- Revenue
- +10.4%
- EPS
- +23.0%
- Free Cash Flow
- -0.6%
Profitability
- Gross Margin
- 85.3%
- Operating Margin
- -90.5%
- Net Margin
- -94.1%
- ROE
- -99.3%
- ROIC
- -56.0%
Balance Sheet
- Debt/Equity
- 1.29
- Current Ratio
- 7.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.